Abstract 2146P
Background
Venous thromboembolism (VTE) in cancer patients is a common complication that requires a multidisciplinary management. In April 2021 we established in the Medical Oncology Department of our hospital a “Cancer-associated thrombosis (CAT) clinic” in order to provide immediate support in prevention and management of VTE to physicians involved in cancer patients’ treatment. The aim of this analysis is to describe the characteristics of patients evaluated, the decisions taken and their results.
Methods
Between May 2021 and April 2023, 124 patients have been evaluated in the “CAT clinic” of the Medical Oncology Department of the Hospital General Universitario Gregorio Marañón (Madrid, Spain) with a mean follow-up of 4.25 months (standard deviation +/- 5.47 months).
Results
The main reason for referral to clinic was VTE treatment (n=120; 96.8%) and the most frequent thrombotic event was pulmonary thromboembolism (n=56; 46.7%). The most common tumors were breast (n=29; 23.4%), lung (n=21; 16.9%) and colon cancer (n=16; 12.9%). Most patients had metastatic disease (n=85; 72.0%), active cancer (n=101; 81.5%) or are receiving antineoplastic therapies (n=95; 76.6%). A modification of anticoagulation therapy was conducted in 99 patients (80.5%): change of anticoagulant drug in 77 patients (most of them from low molecular weight heparins to direct-acting oral anticoagulants [n=51;66.2%]) or change of anticoagulant dose in 49 patients (most of them from therapeutic dose to prophylactic dose in patients with low risk of recurrence and/or high risk of bleeding [n=27;55.1%]). Recurrence of VTE was observed in 8 patients (6.7%) and major bleeding (MB) in 4 patients (3.3%). In particular, 63 patients (52.5%) have received or are receiving apixaban for VTE treatment. No differences were observed between patients receiving apixaban and general population in tumor type, stage, antineoplastic treatment, or thrombotic event. VTE recurrence was seen in 2 patients (3.2%) and MB in 1 patient (1.6%) during apixaban treatment.
Conclusions
The “CAT clinic” has allowed us to adapt the anticoagulant treatment in most of patients, obtaining low complication rates (recurrence/bleeding).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Ortega Morán: Financial Interests, Personal, Invited Speaker: Leo Pharma, Rovi, Menarini, Servier. J. Soto Alsar: Financial Interests, Personal, Invited Speaker: Merck, Ipsen, Pfizer, Leo Pharma; Financial Interests, Personal, Training: MSD, Angelini, Vifor Pharma, Rovi, Amgen, Pfizer, Roche, Janssen, Sanofi; Non-Financial Interests, Personal, Other: Pfizer, Sanofi. R. Jiménez Rodríguez: Financial Interests, Personal, Invited Speaker: Amgen, Kyowa Kyrin; Financial Interests, Personal, Training: Mylan. C. López Jiménez: Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Training: Rovi. R. Martín Lozano: Financial Interests, Personal, Training: Sanofi. G. Torres Perez-Solero: Financial Interests, Personal, Invited Speaker: Adacap, Ipsen, Amgen, Roche, Merck, Servier; Financial Interests, Personal, Advisory Role: Adacap; Financial Interests, Personal, Training: Amgen, Roche, Merck, Lilly, Ipsen, Pfizer, Servier, Sanofi, Rovi, Adacap. M. Martin Jimenez: Financial Interests, Research Grant: Roche, Puma, Novartis; Financial Interests, Advisory Board: AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, Puma, Daiichi Sankyo, Menarini/Stemline, Pfizer; Financial Interests, Invited Speaker: AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, Pfizer. A.J. Munoz Martin: Financial Interests, Personal, Advisory Role: Sanofi, Pfizer, BMS, AstraZeneca, MSD, Roche, GSK, Taiho Oncology, Servier, Leo Pharma; Financial Interests, Personal, Speaker’s Bureau: Rovi, Stada, Menarini, Amgen, Merck; Financial Interests, Personal, Research Funding: Rovi, Celgene, Leo Pharma; Financial Interests, Personal, Training: AstraZeneca, Amgen, Merck, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2142P - Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Presenter: María Esperanza Guirao García
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07
2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Presenter: Pau Mascaró Baselga
Session: Poster session 07